ANL vs TBPH โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
TBPH Captures Institutional Edge (3โ1 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Theravance Biopharma, Inc. (TBPH) driven by superior Valuation, Growth & Margin, Options & Structure while ANL counters with relative strength in Momentum & Technical. Fundamentally, ANL trades at N/M Forward P/E with -123.5% operating margin (+178.1% YoY revenue) versus TBPH at 13.4x Forward P/E and 8.9% operating margin (-20.9% YoY). In options structure, ANL sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against TBPH sits in UNCLASSIFIED (16th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ANL | TBPH | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $677.5M | $884.2M | Larger Scale | TBPH |
| Trailing P/E Ratio Valuation | N/M | 16.4x | Lower Multiple | TBPH |
| Forward P/E Ratio Valuation | N/M | 13.4x | Lower Multiple | TBPH |
| Revenue Growth (YoY) Growth | +178.1% | -20.9% | Higher Growth | ANL |
| Operating Margin (TTM) Profitability | -123.5% | 8.9% | Higher Margin | TBPH |
| Net Profit Margin Profitability | -124.8% | 51.6% | Higher Margin | TBPH |
| Return on Equity (ROE) Capital Efficiency | -20.2% | 20.9% | Higher ROE | TBPH |
| 52-Week Range Position Momentum | 56% ($1โ$17) | 50% ($13โ$21) | Stronger Trend | ANL |
| Beta / 30D Volatility Risk Regime | 2.61ฮฒ ยท 79% Vol | 0.48ฮฒ ยท 2% Vol | Lower Realized Risk | TBPH |
| Unified Institutional Score Composite Signal | 48.3 / 100 (HOLD) | 54.9 / 100 (HOLD) | Higher Composite | TBPH |